A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication of Helicobacter pylori: A Non-Inferiority Clinical Trial

PURPOSE: The emergence of resistant strains has greatly reduced the eradication rate of H. pylori (HP) in conventional bismuth-containing quadruple therapy. Meanwhile, the new 7-day dual therapy with vonoprazan (VPZ) and amoxicillin (AMO) failed to achieve the expected therapeutic effect in China. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Juan, Lv, Lin, Zhu, Yongjun, Zhou, Zhihang, He, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473400/
https://www.ncbi.nlm.nih.gov/pubmed/37662977
http://dx.doi.org/10.2147/IDR.S417711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473400/
https://www.ncbi.nlm.nih.gov/pubmed/37662977
http://dx.doi.org/10.2147/IDR.S417711

Ejemplares similares